Real-world impact of NVX-CoV2373 COVID-19 vaccine in immunocompromised individuals in South Korea
A similar risk of medically attended SARS-CoV-2 infection between IIC and non-IC was observed with both a homologous primary series and homologous or heterologous third and fourth doses of NVX-CoV2373, as well as across a variety of immunocompromising conditions.
Authors
- Jonathan Fix (ORCID: https://orcid.org/0000-0002-4186-0790)
- Eunseon Gwak (ORCID: https://orcid.org/0009-0003-8289-8773)
- Muruga Vadivale
- Manuela H Gschwend
- Seung-Ah Choe
- Matthew D. Rousculp
- Young June Choe
- Erdenetuya Bolormaa
- Kyuwon Kim
Institutions
- Korea University (KR)
- Novavax (United States) (US)
- Korea University (JP)
Publication Details
- Journal
- BMC Public Health
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1186/s12889-026-26592-1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00